NeuroPace FY2025 EPS Forecast Reduced by Cantor Fitzgerald

NeuroPace, Inc. (NASDAQ:NPCE) – Stock analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for NeuroPace in a research report issued to clients and investors on Wednesday, January 29th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will earn ($0.80) per share for the year, down from their prior forecast of ($0.79). The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.07. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The business had revenue of $21.06 million during the quarter, compared to the consensus estimate of $19.33 million. During the same quarter in the prior year, the company earned ($0.28) earnings per share.

A number of other equities research analysts also recently issued reports on NPCE. JPMorgan Chase & Co. boosted their price target on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. UBS Group began coverage on NeuroPace in a research report on Tuesday, January 21st. They set a “buy” rating and a $17.00 target price on the stock. Finally, Wells Fargo & Company upped their price target on shares of NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.80.

NeuroPace Price Performance

Shares of NASDAQ NPCE opened at $13.76 on Friday. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03. NeuroPace has a twelve month low of $5.45 and a twelve month high of $18.15. The firm has a market cap of $410.71 million, a P/E ratio of -13.76 and a beta of 2.02. The company has a 50 day moving average of $11.84 and a 200 day moving average of $8.86.

Insider Buying and Selling at NeuroPace

In other news, insider Martha Morrell sold 3,200 shares of the firm’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $15.01, for a total transaction of $48,032.00. Following the completion of the transaction, the insider now owns 87,062 shares in the company, valued at $1,306,800.62. This trade represents a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 22.20% of the stock is currently owned by insiders.

Institutional Trading of NeuroPace

A number of large investors have recently added to or reduced their stakes in the company. Millennium Management LLC increased its position in NeuroPace by 13.3% in the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock worth $5,186,000 after purchasing an additional 80,324 shares during the last quarter. Financial Advocates Investment Management raised its position in shares of NeuroPace by 20.0% during the 3rd quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock valued at $125,000 after buying an additional 3,000 shares in the last quarter. State Street Corp lifted its holdings in shares of NeuroPace by 9.1% in the 3rd quarter. State Street Corp now owns 155,490 shares of the company’s stock valued at $1,084,000 after acquiring an additional 12,912 shares during the last quarter. Barclays PLC increased its stake in NeuroPace by 346.0% during the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock worth $144,000 after acquiring an additional 16,007 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of NeuroPace by 8.7% in the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock valued at $2,211,000 after purchasing an additional 25,330 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.